Business Development Challenges for Small & Mid-Sized CROs (2026 Update)
Updated: 1 hour ago
Updated 26 October 2026 with H1 2026 funding and M&A data and the ICH E6(R3) Annex 2 timeline. First published in February 2026.
A practical guide to growth, differentiation and client acquisition in early-phase clinical research.
The biggest business development challenges for small and mid-sized CROs are limited sales capacity, long sponsor decision cycles, weak differentiation against global CROs, and a 2026 funding market that concentrates money in fewer, larger biotech rounds. CROs that focus on early-phase work, a narrow therapeutic ICP and structured follow-up win more consistently than those that try to match global players.
Key Takeaways
CRO business development means navigating complex sponsor procurement and multi-stakeholder decisions.
A predictable CRO pipeline depends on consistent outbound outreach and proactive relationship development, not referrals alone.
Small and mid-sized CROs compete on therapeutic expertise, responsiveness and relationship quality, not on price.
In 2026, the funded early-phase sponsor still exists, but there are fewer of them, so targeting matters more than volume.
Fractional BD leadership helps growing CROs build commercial infrastructure without the risk of an early full-time hire.
Small and mid-sized Contract Research Organizations (CROs) play a critical role in the life sciences ecosystem. They bring scientific depth, operational flexibility and therapeutic focus that many sponsors actively seek, especially in early-phase clinical development.
Yet despite strong delivery capabilities, many CROs struggle with business development. Not because they do not provide quality services, but because commercial strategy, lead generation and structured sales execution are often underdeveloped or inconsistent.
This article covers the most common business development challenges for CROs, what changed in 2026, why early-phase focus creates a strategic advantage, and how small and mid-sized CROs can build a sustainable growth strategy without competing head-to-head with global players.
The CRO Market in Numbers (2026)
The global CRO services market is forecast to grow from about USD 93 billion in 2026 to roughly USD 140 billion by 2031, a CAGR near 8.6% (MarketsandMarkets).
Clinical research services make up the largest slice of CRO revenue, around 58%.
Oncology is the single largest therapeutic area, at roughly 35% of the market.
Private biopharma investment reached USD 16 billion across 314 deals in H1 2026, and first financings reached USD 4.1 billion across 95 companies (HSBC Innovation Banking).
The average pharmaceutical B2B sales cycle runs about 138 days, and complex CRO engagements frequently exceed 12 months, so sponsor decisions are slow and committee-driven.
For small and mid-sized CROs, the challenge is rarely market size, it is being seen. Sponsors increasingly favour providers with de-risked, near-term value, and with sales cycles averaging around 138 days the BD work that wins this year's contracts happened two or three quarters ago. Early, consistent pipeline activity is no longer optional. Examples of the results achieved with CROs and CDMOs are documented in our case studies.
What changed for small CROs in 2026
Funding came back, but to fewer sponsors
HSBC Innovation Banking reports that the top 10% of first financings took 63% of the USD 4.1 billion raised in H1 2026. BioPharma Dive's tracker adds that about two-thirds of biotech venture rounds in the first half went to companies that already had a drug in human testing. For a small CRO, this means the sponsors with budget are fewer and further along. A target list built from 2026 financing announcements, filtered on phase and therapeutic area, beats a broad list of early-stage names.
Acquisitions reopen vendor decisions
HSBC also counts 19 venture-backed biopharma acquisitions in H1 2026, ten of them with lead assets in preclinical or Phase I. When a sponsor is acquired, its outsourcing is reviewed by the buyer. CROs that track these deals and reconnect in the first weeks after an announcement keep programs that would otherwise move to the acquirer's preferred providers.
GCP modernisation gives CROs a reason to call
ICH E6(R3) principles and Annex 1 have applied in the EU since 23 July 2025, and the FDA published its final E6(R3) guidance in September 2025. Annex 2, adopted on 3 June 2026, covers decentralised elements, pragmatic designs and real-world data, and becomes effective in the EU on 15 January 2027. Small sponsors rarely have the internal resources to interpret these changes. A CRO that can explain, in one page, how it applies risk-based quality management and remote oversight has a better opening than one sending a generic capabilities deck.
Sponsors shortlist with AI before they call
Biotech teams increasingly ask AI assistants which CROs fit their indication and phase before they contact anyone. A CRO whose therapeutic focus, study types and sponsor profile are not stated clearly on its website is less likely to appear in those shortlists. Clear positioning is now both a sales asset and a visibility asset, as we explain in our H2 2026 BD priorities update.
The Reality of Business Development for CROs Today
For many small and mid-sized CROs, growth depends heavily on existing sponsor relationships, referrals and founder-led selling. This can work in the early years, but it rarely scales.
Business development for CROs today requires structure, positioning and focus, especially as competition increases and sponsor expectations evolve.
Key Business Development Challenges for Small & Mid-Sized CROs
1. Limited or No In-House Sales Team
Many CROs do not have a dedicated sales function. Business development is handled by scientific leadership, operations managers or the CEO, alongside their main job.
The result is predictable: no systematic prospecting, no consistent follow-up and no defined CRO sales strategy. Pipeline development becomes reactive rather than intentional.
2. One-Person BD Teams Stretched Too Thin
When CROs do hire a BD professional, it is often a single person responsible for everything: lead generation, account management, proposal coordination, conferences and networking.
This role quickly becomes unsustainable. Without clear prioritisation and process, even strong BD talent struggles to deliver consistent results in long, complex CRO sales cycles.
3. Scientific Founders Doing Sales Without Structure
Many CRO founders come from clinical operations or scientific backgrounds, and that expertise is invaluable. However, scientific credibility alone is not a business development strategy.
Common issues include no defined Ideal Customer Profile (ICP), no segmentation by trial phase or therapeutic area, and inconsistent messaging across outreach. The result is missed opportunities and inefficient client acquisition.
4. Long CRO Sales Cycles
CRO sales cycles are inherently long. Sponsors need time to secure funding, align internal stakeholders, finalise protocols and compare vendors. Without structured follow-up and pipeline management, opportunities quietly disappear.
This is one of the most underestimated challenges in CRO sales execution. A structured life science lead generation process, with disciplined follow-up and pipeline management, is what turns these long cycles into a predictable stream of qualified conversations.
5. Difficulty Competing with Global CROs
Small CROs often believe they are losing deals because they are too small. In reality, the problem is usually positioning, not size.
Global CROs dominate Phase III programs, large multinational trials and full-service mandates. Trying to compete in those segments is rarely an effective growth strategy for smaller organisations.
6. Lack of Clear Differentiation
Many CROs describe themselves as flexible, high quality and client-focused. These claims may be true, but they are not differentiators.
Without a clearly articulated value proposition, a CRO's marketing and sales efforts blend into the background, and sponsors cannot see why they should engage. In 2026, the same vagueness also keeps a CRO out of AI-generated shortlists.
Why Early-Phase Focus Is a Winning Strategy for CROs
Phase I and II Trials Are Led by Small & Mid-Sized Biotechs
Early-phase development is largely driven by emerging biotech companies, virtual biotechs and academic spin-offs. These sponsors often prefer specialised CROs that can move fast, adapt and provide hands-on scientific collaboration. This is where small CROs can outperform larger competitors.
Early-Phase Sponsors Value Expertise and Agility, Not Size
In Phase I and II, decisions are faster, scientific dialogue matters more than scale, and access to senior CRO leadership is valued. A business development strategy aligned with early-phase trials creates stronger conversion and repeat business.
Phase III Trials Are Dominated by Global CROs
Large Phase III programs require global infrastructure, large operational teams and extensive regulatory coverage. For most small CROs, competing here drains resources without delivering predictable growth.
Early-Phase Trials Enable Long-Term Partnerships
Early success creates momentum through proof-of-concept trials, extension studies and follow-on programs. This makes early-phase work a powerful engine for sustainable growth, not just short-term revenue.
Ideal Target Clients for Small & Mid-Sized CROs
A successful CRO commercial strategy starts with focus. High-fit sponsor profiles include:
Pre-clinical to Phase II biotech companies: limited internal clinical operations, high reliance on external expertise and a need for strategic guidance.
Virtual biotech companies: outsourced-by-design operating models that align naturally with specialised CRO services.
Academic spin-offs: scientifically innovative, but often unfamiliar with CRO selection processes.
Medical device startups: niche protocols and smaller, agile trials.
Emerging pharma without internal clinical operations: they need operational partners, not vendors.
In 2026, add one filter to every segment: has the company raised money in the last 12 months, and is its lead program at a stage your CRO serves? Defining and prioritising these segments is essential for effective client acquisition.
Importance of Therapeutic Area Alignment
Sponsors Choose CROs Based on Disease Expertise
Therapeutic alignment is one of the strongest decision drivers in CRO selection. Sponsors want partners who understand the disease biology, know the relevant endpoints and anticipate operational risks.
Oncology and CNS Demand Deep Operational Knowledge
Complex indications require experienced project teams, established site networks and regulatory nuance. Generic messaging fails here.
Rare Disease and Orphan Indications Favour Specialised CROs
Small patient populations, adaptive designs and biomarker-driven trials reward specialisation. This is a natural advantage for niche CROs with focused experience.
Biomarker and Translational Expertise Is a Differentiator
CROs that can connect clinical operations, biomarkers and translational science position themselves as strategic partners, not just service providers.
Align Messaging with Sponsor Pipelines
Effective CRO outreach starts with understanding the sponsor's pipeline, referencing its active indications and speaking its scientific language. This dramatically improves engagement and response rates.
Strategic Partnerships as a CRO Growth Lever
Partnering with Complementary CROs
Instead of building everything in-house, CROs can collaborate with specialists to extend their service offering while staying focused.
Offering Integrated Services Without Becoming a Large CRO
Strategic partnerships let CROs offer end-to-end solutions, keep their agility and avoid operational bloat.
Building Referral Ecosystems
Trusted referral networks create warm introductions, higher-quality leads and shorter sales cycles.
Creating Virtual Full-Service Models
Sponsors increasingly accept modular service models, provided execution is seamless. This approach strengthens credibility without sacrificing specialisation.
Why Outsourced Business Development Makes Sense for CROs
For many organisations, outsourced business development is a strategic choice, not a compromise.
Cost-Effective Alternative to Internal Sales Teams
No long hiring cycle, no fixed overhead and immediate execution.
Access to Established Life Sciences Networks
Experienced BD partners bring existing sponsor relationships, market insight and real-time feedback from the field.
Structured Lead Generation and Qualification
Outsourced teams implement ICP definition, account-based targeting and CRM-driven follow-up, which changes how CROs win new clients. Prospecting works best when it sits within a structured commercial strategy, which is where a fractional business development partner can align outreach, positioning and partnership strategy.
Alignment With CRO Positioning and Therapeutic Focus
A strong business development approach for CROs starts with positioning, messaging and strategic focus, not generic outreach.
Faster Access to Decision-Makers
Structured outreach, relationship-led engagement and industry credibility accelerate pipeline development without damaging reputation.
Building a Sustainable CRO Growth Strategy
For small and mid-sized CROs, growth does not come from doing more. It comes from doing less, better. A strong CRO business development strategy combines clear market focus, early-phase specialisation, therapeutic alignment, structured sales execution and strategic partnerships.
When marketing, sales and delivery are aligned, CROs move from opportunistic selling to predictable growth. If you are setting next year's targets now, our 2027 business development plan guide shows how to turn a revenue goal into the meetings and accounts it requires.
Final Thoughts
Small and mid-sized CROs are not at a disadvantage. They are playing a different game. By focusing on early-phase development, niche expertise and structured business development, CROs can win better-fit sponsors, build long-term partnerships and grow without adding headcount unnecessarily.
The challenge is not demand. It is commercial clarity and execution.
How do small CROs find new clients?
Small and mid-sized CROs win new clients through a defined ICP, relationship-led outreach, conference meetings, credibility proof and consistent follow-up across long procurement cycles.
Define a narrow ICP by therapeutic area, study phase and sponsor size
Prioritise sponsors that raised money in the last 12 months
Build credibility with case studies and sponsor references before the first call
Generate qualified meetings at industry events such as BIO-Europe, DCAT, BIO and CPHI
Run relationship-led outreach across email and LinkedIn
Follow up consistently through the long sponsor decision cycle
Frequently asked questions
What are the biggest business development challenges for small and mid-sized CROs?
Small and mid-sized CROs typically struggle with limited BD capacity, long and committee-driven sponsor decisions, weak differentiation against global CROs, and difficulty reaching decision-makers at pharma and biotech companies. In 2026 a fifth challenge was added: biotech funding is concentrated in fewer, larger rounds, so the pool of well-funded early-phase sponsors is smaller.
What changed for CRO business development in 2026?
Three things. Biotech funding recovered but concentrated: HSBC Innovation Banking reports that the top 10% of first financings took 63% of the USD 4.1 billion raised in H1 2026. Venture-backed biotechs are being acquired early, which reopens vendor decisions. And ICH E6(R3) Annex 2, effective in the EU on 15 January 2027, gives CROs a concrete reason to talk to sponsors about risk-based and decentralised trial oversight.
How can a CRO build a stronger sales pipeline?
By combining targeted outbound prospecting toward recently funded sponsors, pre-booked meetings at events such as BIO-Europe, DCAT and BIO, and inbound content that explains the CRO's therapeutic and service area expertise clearly enough for buyers and AI assistants to cite it.
Should small CROs outsource their business development?
Often, yes. A fractional model gives a small CRO experienced business development execution, ICP definition and structured follow-up without the cost, hiring time and risk of a full-time senior hire. It works best when the CRO's leadership stays involved in scientific conversations with sponsors.
How do small CROs find new clients?
Small and mid-sized CROs win new clients through a defined ICP, relationship-led outreach, conference meetings, credibility proof and consistent follow-up across long procurement cycles. The key steps are: define a narrow ICP by therapeutic area, study phase and sponsor size, build credibility with case studies, generate qualified meetings at industry events, run relationship-led outreach across email and LinkedIn, and follow up through the long sponsor decision cycle.
Related reading
Written by Imen Jelassi, PharmD, founder and CEO of Corstrate. Imen started her career as a CRA in a CRO and has worked in business development for life sciences service providers since 2012. If you want help building a predictable pipeline for your CRO, get in touch.
Comments